A. sativum and cilostazol were able to inhibit myointimal hyperplasia in 40.9% and 54.64% of animals, respectively, as compared to the negative control (0.9% physiological saline solution), demonstrating the effectiveness of both substances. Although the proportion of animals exhibiting myointimal hyperplasia inhibition was 13.74% higher with cilostazol than with A. sativum, the fact that cilostazol is a drug that is already the active ingredient should be considered. Thus, even though a plant in its original form was used, without isolation of the active principle, a statistically similar result was obtained.